[Mechanism of action of antiplatelet medication].
D000067956:Adenylyl Cyclase Inhibitors; D000925:Anticoagulants / Q000494:pharmacology*; D001095:Arachidonic Acids / Q000378:metabolism; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D002121:Calcium Channel Blockers / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010740:Phospholipases / Q000037:antagonists & inhibitors; D010973:Platelet Adhesiveness / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects*; D011448:Prostaglandin Antagonists / Q000494:pharmacology; D011956:Receptors, Cell Surface / Q000187:drug effects / Q000502:physiology; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors
D000067956:Adenylyl Cyclase Inhibitors; D000925:Anticoagulants; D001095:Arachidonic Acids; D002121:Calcium Channel Blockers; D016861:Cyclooxygenase Inhibitors; D010726:Phosphodiesterase Inhibitors; D011448:Prostaglandin Antagonists; D011956:Receptors, Cell Surface; D010740:Phospholipases; D013930:Thromboxane-A Synthase
Mecanismo de acción de la medicación antiplaquetaria.